UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B

Clinical gastroenterology and hepatology, 2018-04, Vol.16 (4), p.575-583.e2

2018

Volltextzugriff (PDF)

Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes

Hepatology (Baltimore, Md.), 2023-02, Vol.77 (2), p.606-618

2023

Volltextzugriff (PDF)

High prevalence of non-alcoholic fatty liver disease in the Chinese - results from the Hong Kong liver health census

Liver international, 2015-02, Vol.35 (2), p.542-549

2015

Volltextzugriff (PDF)

Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down‐regulating the nuclear factor‐kappa B signaling

Journal of digestive diseases, 2020-01, Vol.21 (1), p.38-45

2020

Volltextzugriff (PDF)

Fibrosis evolution in chronic hepatitis B e antigen‐negative patients across a 10‐year interval

Journal of viral hepatitis, 2019-07, Vol.26 (7), p.818-827

2019

Volltextzugriff (PDF)

Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes

Diabetes care, 2021-09, Vol.44 (9), p.2089-2097

2021

Volltextzugriff (PDF)

Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study

Hepatology (Baltimore, Md.), 2017-05, Vol.65 (5), p.1451-1461

2017

Volltextzugriff (PDF)

Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study

Gut, 2024-08, Vol.73 (8), p.1313-1320

2024

Volltextzugriff (PDF)

Hepatitis B core‐related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma

Journal of viral hepatitis, 2019-12, Vol.26 (12), p.1473-1480

2019

Volltextzugriff (PDF)

Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment

Journal of gastroenterology and hepatology, 2014-03, Vol.29 (3), p.428-434

2014

Volltextzugriff (PDF)

Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

The American journal of gastroenterology, 2024-03, Vol.119 (3), p.486-496

2024

Volltextzugriff (PDF)

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Clinical and molecular hepatology, 2023-07, Vol.29 (3), p.690-692

2023

Volltextzugriff (PDF)

A large real‐world cohort study examining the effects of long‐term entecavir on hepatocellular carcinoma and HBsAg seroclearance

Journal of viral hepatitis, 2020-04, Vol.27 (4), p.397-406

2020

Volltextzugriff (PDF)

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection

Viruses, 2021-06, Vol.13 (6), p.1169

2021

Volltextzugriff (PDF)

Acute-on-chronic liver failure in chronic hepatitis B

Journal of gastroenterology and hepatology, 2012-04, Vol.27 (4), p.662-669

2012

Volltextzugriff (PDF)

Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study

Journal of viral hepatitis, 2023-04, Vol.30 (4), p.319-326

2023

Volltextzugriff (PDF)

Response to Liu et al., and Björnsson and Björnsson

The American journal of gastroenterology, 2021-05, Vol.116 (5), p.1091-1092

2021

Volltextzugriff (PDF)

Gut microbiome and resistome changes during the first wave of the COVID-19 pandemic in comparison with pre-pandemic travel-related changes

Journal of travel medicine, 2021-10, Vol.28 (7)

2021

Volltextzugriff (PDF)

Magnetic resonance imaging metrics and the predictability of adverse outcomes in on‐treatment Asian chronic hepatitis B

Journal of gastroenterology and hepatology, 2022-06, Vol.37 (6), p.1139-1147

2022

Volltextzugriff (PDF)

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

Hepatology (Baltimore, Md.), 2013-09, Vol.58 (3), p.923-931

2013

Volltextzugriff (PDF)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes

Alimentary pharmacology & therapeutics, 2024-11, Vol.60 (10), p.1398-1408

2024

Volltextzugriff (PDF)

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

Alimentary pharmacology & therapeutics, 2024-01, Vol.59 (2), p.217-229

2024

Volltextzugriff (PDF)

Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)

The American journal of gastroenterology, 2023-09, Vol.118 (9), p.1601-1608

2023

Volltextzugriff (PDF)

Screening strategy for non-alcoholic fatty liver disease

Clinical and molecular hepatology, 2023-02, Vol.29 (Suppl), p.S103-S122

2023

Volltextzugriff (PDF)

Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial

Helicobacter (Cambridge, Mass.), 2024-09, Vol.29 (5), p.e13133-n/a

2024

Volltextzugriff (PDF)

26 – 50 von 438

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(401)
Mit Volltextzugriff
(382)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(259)
Life Sciences & Biomedicine
(243)
Gastroenterology & Hepatology
(171)
Humans
(170)
Female
(109)
Male
(106)
Hepatitis B
(100)
Middle Aged
(97)
Adult
(83)
Hepatitis B Virus
(76)
Hepatitis
(70)
Hepatitis B, Chronic - Drug Therapy
(65)
Aged
(60)
Antiviral Agents - Therapeutic Use
(57)
Liver
(54)
Hepatocellular Carcinoma
(51)
Hepatitis B Virus - Genetics
(49)
Hepatology
(46)
Liver Cirrhosis
(44)
Patients
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Hepatology
(70)
Gastroenterology
(33)
Clinical And Molecular Hepatology
(21)
Gut And Liver
(20)
The American Journal Of Gastroenterology
(18)
Plos One
(17)
Journal Of Gastroenterology And Hepatology
(14)
Gut
(13)
Hepatology
(13)
Hepatology International
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B

Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes

High prevalence of non-alcoholic fatty liver disease in the Chinese - results from the Hong Kong liver health census

Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down‐regulating the nuclear factor‐kappa B signaling

Fibrosis evolution in chronic hepatitis B e antigen‐negative patients across a 10‐year interval

Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes

Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study

Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study

Hepatitis B core‐related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma

Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment

Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

A large real‐world cohort study examining the effects of long‐term entecavir on hepatocellular carcinoma and HBsAg seroclearance

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection

Acute-on-chronic liver failure in chronic hepatitis B

Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study

Response to Liu et al., and Björnsson and Björnsson

Gut microbiome and resistome changes during the first wave of the COVID-19 pandemic in comparison with pre-pandemic travel-related changes

Magnetic resonance imaging metrics and the predictability of adverse outcomes in on‐treatment Asian chronic hepatitis B

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)

Screening strategy for non-alcoholic fatty liver disease

Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial

Suchergebnisse filtern